Form 8-K

8-K — KESTRA MEDICAL TECHNOLOGIES, LTD.

Accession: 0001193125-26-303169

Filed: 2026-07-14

Period: 2026-07-10

CIK: 0001877184

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Entry into a Material Definitive Agreement

Item: Termination of a Material Definitive Agreement

Item: Results of Operations and Financial Condition

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Financial Statements and Exhibits

Documents

8-K — ck0001877184-20260710.htm (Primary)

EX-99.1 (ck0001877184-ex99_1.htm)

GRAPHIC (img39479847_0.gif)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ck0001877184-20260710.htm · Sequence: 1

8-K

false000187718400-000000000018771842026-07-102026-07-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2026

KESTRA MEDICAL TECHNOLOGIES, LTD.

(Exact name of Registrant as Specified in Its Charter)

Bermuda

001-42549

Not Applicable

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

3933 Lake Washington Blvd NE

Suite 200

Kirkland, Washington

98033

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (425) 279-8002

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Shares, par value $1.00 per share

KMTS

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On July 10, 2026, Kestra Medical Technologies, Ltd. (the “Company”), its wholly-owned subsidiary, Kestra Medical Technologies, Inc. (the “Borrower”) and other credit parties thereto (collectively with the Borrower and the Company, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP (each, a “Lender”), which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent (the “Collateral Agent”). The Loan Agreement provides for a five-year senior secured term loan facility of up to $200.0 million, divided into four tranches: (i) a committed Tranche A Loan in an aggregate principal amount of $75.0 million (the “Tranche A Loan”) which was funded on July 10, 2026 (the “Tranche A Closing Date”); (ii) a committed Tranche B Loan in an aggregate principal of $25.0 million (the “Tranche B Loan”) which may be requested, subject to certain limited conditions, at the Borrower’s option through July 31, 2027; (iii) a committed Tranche C Loan in an aggregate principal amount of $50.0 million (the “Tranche C Loan”) which is available to the Borrower upon reaching a trailing twelve-month revenue of $150.0 million and which may be requested on or prior to June 30, 2028 and (iv) an uncommitted Tranche D Loan for acquisitions at the Company’s option in aggregate principal amount of $50.0 million (the “Tranche D Loan” and collectively with the Tranche A Loan, the Tranche B Loan, and the Tranche C Loan, the “Term Loans”), subject to certain limited conditions and upon approval of the Lenders, on such date mutually agreed upon between the Lenders and the Borrower.

The Borrower’s net proceeds from the Tranche A Loan were approximately $20.0 million, after deducting estimated debt issuance costs, fees and expenses, and repaying in full the Borrower's obligations under its Prior Loan Agreement with its Prior Lender (each as defined in Item 1.02 below) on July 10, 2026. The remaining proceeds will be used to fund the Company’s general corporate and working capital requirements.

The Term Loans mature on July 10, 2031 (the “Maturity Date”). The Term Loans bear interest as a variable rate per annum equal to a 5.50% plus three-month Secured Overnight Financing Rate (“SOFR”) with a SOFR floor of 3.25%. Interest is due and payable on the last day of each quarter, with payment beginning in the calendar quarter immediately following the Tranche A Closing Date. The Loan Agreement requires the Borrower to pay an amount equal to 1.75% of the Lenders’ total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan. The Term Loans provide for 48 months of interest-only payments and amortize in four equal quarterly installments beginning in the second fiscal quarter of 2030 and continuing through the Maturity Date. The Term Loans may be voluntarily prepaid in whole (but not in part), and are subject to make-whole, prepayment premium and exit fees, and must be prepaid upon a Change in Control (as defined in the Loan Agreement).

Pursuant to the Guaranty and Security Agreement, Irish Debenture and the Irish Share Charge, the Credit Parties granted the Collateral Agent a security interest in substantially all of the Company and its subsidiaries’ assets and property, including intellectual property, to secure the payment of all amounts owed to Lenders under the Loan Agreement.

The Loan Agreement contains customary affirmative covenants including, without limitation, information delivery requirements, obligations to maintain insurance, preservation of intellectual property and regulatory approvals, and compliance with applicable laws. The Loan Agreement also contains customary restrictive covenants, including, without limitation, limitations on the incurrence of additional indebtedness, limitations on the incurrence of liens, restrictions on the payment of dividends and other restricted payments, and restrictions on mergers and similar transactions. The Borrower is required to maintain a minimum liquidity of at least $20.0 million in cash and cash equivalents at all times. The Loan Agreement also contains customary representation and warranties and other customary provisions, such as confidentiality obligations and indemnification rights for the benefit of the Lenders.

The foregoing summary of the terms of the Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the actual text of the Loan Agreement, which will be filed with the Company’s Annual Report on Form 10-K for the period ending on April 30, 2026.

Item 1.02 Termination of a Material Definitive Agreement.

On September 29, 2023, the Borrower, the Company and the other credit parties thereto entered into that certain loan agreement (as amended and restated, the “Prior Loan Agreement”) with Perceptive Credit Holdings IV, LP (the “Prior Lender”). In connection with the entry into the Loan Agreement on July 10, 2026, the Prior Loan Agreement and the other loan documents associated therewith were terminated, the payment and other obligations of the Borrower under the Prior Loan Agreement were paid in full and discharged, and Prior Lender’s security interests in the Company’s assets and property were released.

Item 2.02 Results of Operations and Financial Condition.

On July 14, 2026, the Company issued a press release announcing its financial results for the fiscal quarter ended April 30, 2026. A copy of the press release, dated July 14, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit

Number

Description

99.1

Press Release of Kestra Medical Technologies, Ltd., dated July 14, 2026

104

Cover Page Interactive Data File, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Kestra Medical Technologies, Ltd.

Date: July 14, 2026

By:

/s/ Brian Webster

Name:

Brian Webster

Title:

President and Chief Executive Officer

EX-99.1

Filename: ck0001877184-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results

KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2026.

Financial Highlights

•

Fiscal 4Q26 revenue of $28.6 million, an increase of 66% compared to the prior year period.

•

FY26 revenue of $95.1 million, an increase of 59% compared to FY25.

•

Fiscal 4Q26 gross margin of 54.8% compared to 44.3% in the prior year period.

•

FY26 gross margin of 51.4% compared to 40.5% in FY25.

•

FY27 revenue guidance of $137 million, an increase of 44% compared to fiscal year 2026.

“Kestra concluded fiscal year 2026 with another strong quarter of financial performance, generating revenue growth of 66% while expanding gross margin to 55%,” said Brian Webster, President and CEO. “In fiscal year 2026, the ASSURE® system protected 18,000 patients from sudden cardiac arrest, a testament to the dedication of our mission-driven team. We also made significant progress on key operational objectives, including rapid growth of our commercial organization, release of compelling primary results from our FDA post-approval study, launch of our latest algorithm update, fortification of our balance sheet, and entrance into a strategic collaboration with Biobeat Technologies. We remain confident that our focus on innovation and executing on our commitments to prescribers and their patients will continue to drive market expansion and advance Kestra on its path to market leadership.”

Fourth Quarter Fiscal 2026 Financial Results

•

Total revenue was $28.6 million, an increase of 66% compared to the prior year period.

6,357 prescriptions were written for the ASSURE® system, an increase of 63% compared to the prior year period.

Revenue growth was driven primarily by higher market share and wearable cardioverter defibrillator (WCD) market expansion. Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management capabilities.

•

Gross profit was $15.7 million compared to $7.6 million in the prior year period.

Gross margin expanded to 54.8% compared to 44.3% in the prior year period, driven by volume leverage, a higher mix of in-network patients and execution of planned cost improvement programs.

•

GAAP operating expenses were $55.0 million compared to $55.8 million in the prior year period.

Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses* were $44.7 million compared to $29.7 million in the prior year period. The increase was primarily attributable to growth in expenses related to the company’s accelerated commercial expansion.

•

GAAP net loss was $38.8 million compared to GAAP net loss of $51.1 million in the prior year period.

Adjusted EBITDA* loss was $26.7 million compared to an adjusted EBITDA loss of $20.3 million in the prior year period.

•

Cash and cash equivalents, and investments totaled $262.2 million as of April 30, 2026.

Net cash used in operating activities was $18.7 million, a reduction from $24.1 million in the prior year period.

Fiscal Year 2026 Financial Results

•

Total revenue was $95.1 million, an increase of 59% compared to FY25.

20,720 prescriptions were written for the ASSURE® system, an increase of 57% compared to FY25.

•

Gross profit was $48.9 million compared to $24.2 million in FY25.

Gross margin expanded to 51.4% compared to 40.5% in FY25.

•

GAAP operating expenses were $183.6 million compared to $130.6 million in FY25.

Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses* were $144.6 million compared to $100.6 million in FY25.

•

GAAP net loss was $131.6 million compared to GAAP net loss of $113.8 million in FY25.

Adjusted EBITDA* loss was $87.0 million compared to an adjusted EBITDA loss of $68.4 million in FY25.

*Adjusted operating expenses and adjusted EBITDA are non-GAAP financial measures. See “Use of Non-GAAP Financial Measures” below for additional information. Reconciliations of adjusted operating expenses and adjusted EBITDA to the most directly comparable GAAP measure are included in this press release.

Fiscal Year 2027 Revenue Guidance

Kestra expects revenue of $137 million in FY27, which would represent growth of 44% compared to FY26.

Webcast and Conference Call

Kestra will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website.

About Kestra

Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.

Use of Non-GAAP Financial Measures

This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including adjusted operating expense and adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.

Adjusted operating expense is calculated as operating expenses, as adjusted to exclude share-based compensation expense and non-recurring expenses. Adjusted EBITDA is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense,

share-based compensation expense, and non-recurring expenses. Both metrics are presented because management believes they will allow investors to view Kestra’s performance in a manner similar to the method used by management to evaluate Kestra’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of adjusted operating expenses and adjusted EBITDA, in addition to considering Kestra’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.

The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of adjusted operating expenses and adjusted EBITDA reported in this press release to the most comparable respective GAAP measure for the respective periods appears in the tables captioned “Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses” and “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.

Forward-Looking Statements

Except where otherwise noted, the information contained in this press release is as of July 14, 2026. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, Kestra undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “continue,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “advance,” “remain,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; risks and uncertainties related to market conditions; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2026 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings,

when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.

Investor Relations

Neil Bhalodkar

neil.bhalodkar@kestramedical.com

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share amounts)

(unaudited)

Three Months Ended April 30,

Year Ended April 30,

2026

2025

2026

2025

Revenue

28,638

17,233

95,126

59,815

Cost of revenue

12,956

9,600

46,263

35,605

Gross profit

15,682

7,633

48,863

24,210

Operating expenses:

Research and development

5,634

5,386

19,484

15,652

Selling, general and administrative

49,392

50,459

164,120

114,936

Total operating expenses

55,026

55,845

183,604

130,588

Loss from operations

(39,344

)

(48,212

)

(134,741

)

(106,378

)

Other expense (income):

Interest expense

1,844

1,760

7,546

7,734

Interest income

(2,226

)

(1,656

)

(8,351

)

(3,199

)

Other expense (income)

(319

)

2,693

(2,618

)

2,766

Net loss before provision for income taxes

(38,643

)

(51,009

)

(131,318

)

(113,679

)

Provision for income taxes

192

102

294

135

Net loss

(38,835

)

(51,111

)

(131,612

)

(113,814

)

Less: Undeclared preferred stock dividends

—

3,291

—

12,321

Net loss attributable to common shareholders, basic and diluted

(38,835

)

(54,402

)

(131,612

)

(126,135

)

Net loss per share attributable to common shareholders, basic and diluted

(0.67

)

(2.21

)

(2.43

)

(5.13

)

Weighted-average shares of common shares outstanding, basic and diluted

58,396,698

24,583,745

54,184,698

24,583,745

Other comprehensive loss:

Net loss

(38,835

)

(51,111

)

(131,612

)

(113,814

)

Unrealized loss on marketable securities

(218

)

—

(218

)

—

Comprehensive loss

(39,053

)

(51,111

)

(131,830

)

(113,814

)

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

(unaudited)

April 30,

2026

2025

Assets

Current assets

Cash and cash equivalents

99,710

237,595

Short-term investments

96,724

—

Accounts receivable, net

14,542

8,081

Disposable medical equipment supplies

6,706

6,572

Prepaid expenses and other current assets

4,677

3,080

Total current assets

222,359

255,328

Long-term investments

65,767

—

Right-of-use assets

3,364

2,078

Deposits

1,761

2,021

Restricted cash

334

Property and equipment, net

59,090

34,830

Other long-term assets

5,790

1,153

Total assets

358,465

295,744

Liabilities and Shareholders’ Equity

Current liabilities

Accounts payable

27,295

23,961

Accrued liabilities

23,046

13,829

Operating lease liabilities, current portion

187

Total current liabilities

50,372

37,977

Operating lease liabilities, net of current portion

4,111

3,026

Warrant liabilities

1,369

8,097

Other long-term liabilities

306

140

Long-term debt, net

42,649

41,098

Total liabilities

98,807

90,338

Commitments and contingencies

Shareholders’ equity

Common Shares, $1.00 par value; 100,000,000 shares authorized as of April 30, 2026 and April 30, 2025; 58,383,924 issued and outstanding as of April 30, 2026 and 51,348,656 shares issued and outstanding as of April 30, 2025

58,384

51,349

Additional paid-in capital

853,353

674,306

Accumulated other comprehensive loss

(218

)

—

Accumulated deficit

(651,861

)

(520,249

)

Total shareholders’ equity

259,658

205,406

Total liabilities and shareholders’ equity

358,465

295,744

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

Year Ended April 30,

2026

2025

Cash flows from operating activities

Net loss

(131,612

)

(113,814

)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

8,709

7,968

Loss on disposal of property and equipment

1,161

1,340

Reserve for equipment and supplies

2,435

754

Provision for uncollectible accounts receivable

2,596

2,694

Amortization (accretion) of premiums (discounts) on securities, net

(106

)

—

Interest paid-in-kind

—

855

Amortization of debt discounts and issuance costs

1,874

1,400

Share-based compensation expense

33,644

24,270

Non-cash lease expense

326

416

Deferred income tax expense

166

Change in fair value of warrant liabilities

(2,673

)

2,648

Changes in operating assets and liabilities:

Disposable medical equipment supplies

(458

)

(3,443

)

Prepaid expenses and other current assets

(563

)

(1,852

)

Accounts receivable

(9,056

)

(8,777

)

Accounts payable

4,302

2,842

Accrued liabilities

8,197

4,617

Operating lease liabilities

(685

)

370

Other long-term assets

Net cash used in operating activities

(81,703

)

(77,608

)

Cash flows from investing activities

Purchases of property and equipment

(34,892

)

(22,936

)

Deposits for medical rental equipment

(528

)

(655

)

Refund of deposits for medical rental equipment

184

283

Investment in equity security

(5,000

)

—

Purchase of marketable securities

(163,041

)

—

Net cash used in investing activities

(203,277

)

(23,308

)

Cash flows from financing activities

Proceeds from issuance of redeemable preferred stock

—

103,400

Proceeds from issuance of common stock

149,291

215,789

Proceeds from issuance of stock to non-controlling interest

—

17,100

Proceeds from capital contributions

—

2,374

Payment of IPO offering costs

—

(3,523

)

Payment of equity issuance costs

(2,466

)

(3,224

)

Deemed dividend for payments to third party on behalf of shareholder

(323

)

(1,654

)

Proceeds from stock option exercises

593

—

Net cash provided by financing activities

147,095

330,262

Net increase (decrease) in cash, cash equivalents and restricted cash

(137,885

)

229,346

Cash, cash equivalents and restricted cash

Beginning of period

237,929

8,583

End of period

100,044

237,929

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO CASH, CASH EQUIVALENTS AND INVESTMENTS

(in thousands)

(unaudited)

Year Ended April 30,

2026

2025

Cash, cash equivalents and restricted cash

100,044

237,929

Add: Short-term investments

96,724

—

Add: Long-term investments

65,767

—

Less: Restricted cash

(334

)

(334

)

Cash, cash equivalents, and investments

262,201

237,595

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

(in thousands)

(unaudited)

Three Months Ended April 30,

Year Ended April 30,

2026

2025

2026

2025

GAAP Net loss

(38,835

)

(51,111

)

(131,612

)

(113,814

)

Non-GAAP Adjustments:

Interest expense

1,844

1,760

7,546

7,734

Interest income

(2,226

)

(1,656

)

(8,351

)

(3,199

)

Other expense (income)

(319

)

2,693

(2,618

)

2,766

Provision for income taxes

192

102

294

135

Depreciation expense

2,325

1,836

8,709

7,968

Share-based compensation expense

10,304

22,313

33,644

24,271

Non-recurring expenses

—

3,809

5,396

5,736

Adjusted EBITDA

(26,715

)

(20,254

)

(86,992

)

(68,403

)

RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES

(in thousands)

(unaudited)

Three Months Ended April 30,

Year Ended April 30,

2026

2025

2026

2025

GAAP Operating Expenses

55,026

55,845

183,604

130,588

Non-GAAP Adjustments:

Share-based compensation expense

10,304

22,313

33,644

24,271

Non-recurring expenses

—

3,809

5,396

5,736

Adjusted Operating Expenses

44,722

29,723

144,564

100,581

GRAPHIC

Filename: img39479847_0.gif · Sequence: 3

Binary file (6011 bytes)

Download img39479847_0.gif

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Document and Entity Information

Jul. 10, 2026

Cover [Abstract]

Entity Tax Identification Number

00-0000000

Amendment Flag

false

Entity Central Index Key

0001877184

Document Type

8-K

Document Period End Date

Jul. 10, 2026

Entity Registrant Name

KESTRA MEDICAL TECHNOLOGIES, LTD.

Entity Incorporation State Country Code

Entity File Number

001-42549

Entity Address, Address Line One

3933 Lake Washington Blvd NE

Entity Address, Address Line Two

Suite 200

Entity Address, City or Town

Kirkland

Entity Address, State or Province

Entity Address, Postal Zip Code

98033

City Area Code

425

Local Phone Number

279-8002

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Shares, par value $1.00 per share

Trading Symbol

KMTS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration